Press Releases
Back to Previous Page
 


In the News


MilliporeSigma Makes Major Investment in New Singapore Laboratory
  • First GMP BioReliance® biosafety testing lab in Asia Pacific offering critical testing services to bring life-changing therapies to market
  • Extensive range of upstream and downstream bioprocessing solutions through M Lab™ Collaboration Center, Media Development Services Lab and imMEDIAte Advantage™ Lab

Singapore, September 18, 2018 — MilliporeSigma, the vibrant science and technology company, today announced the opening of a new 3,800-square-meter laboratory in Singapore. The new, $20 million SGD lab is the first of its kind outside of the US and UK, and the first in Singapore. Biologics testing is a major step in the drug development process to ensure sterility, safety and overall quality of customers’ biological drug products.

"This investment underscores our commitment to Singapore as an important hub for MilliporeSigma,” said Udit Batra, Member of the Executive Board, Merck KGaA, Darmstadt, Germany, CEO MilliporeSigma. “Our new BioReliance® lab in Singapore is the first of its kind for biomanufacturing in this region. And our reimagined M Lab™ Collaboration Center, which recreates an actual manufacturing environment, emerged as part of our close work with the Singapore Economic Development Board. We thank the Board for their partnership as we continue to serve the growing needs of our pharma and biotech customers in bringing new therapies to market.”

Singapore is at the heart of the Asia Pacific region, and is the Asian headquarters to many multinational pharmaceutical organizations that have a significant manufacturing footprint on the island. Its vibrant ecosystem has also attracted local Life Science companies and start-ups to establish a presence here.

“The establishment of MilliporeSigma’s biosafety testing lab will strengthen Singapore’s competitiveness as a leading global site for biologics manufacturing,” said Dr. Beh Swan Gin, chairman of Singapore Economic Development Board. “The company’s M Lab™ Collaboration Centre is also a welcome addition to Singapore’s life science innovation ecosystem. Both projects will provide Singaporeans with the opportunity to acquire highly-skilled and specialised capabilities.”

MilliporeSigma provides the industry’s most comprehensive portfolio of high-quality products, services and testing for biopharmaceutical manufacturing.

BioReliance® Biosafety Testing Lab

MilliporeSigma’s BioReliance® biosafety testing services portfolio delivers biosafety testing services to the global pharmaceutical and biotech industry. These crucial safety-testing services ensure the safe release of leading medicines to patients around the world.

M Lab™ Collaboration Center

MilliporeSigma’s M Lab™ Collaboration Center offers non-GMP lab space for training, hands-on demonstrations and process optimization, supported by MilliporeSigma’s technical experts. Designed to recreate an actual manufacturing environment, the center in Singapore is the latest addition to MilliporeSigma’s network of nine M Lab™ Collaboration Centers worldwide.

The flexible lab allows customers to recreate their specific processes for troubleshooting critical process issues without impacting their own production line. The center includes an upgraded suite of digital interactive applications for knowledge sharing and technical exploration.

MilliporeSigma is the world’s oldest pharmaceuticals and chemicals company, celebrating its 350th anniversary this year. The company is continuing its legacy of defining the future and leading the evolution of drug development and manufacturing of life-enhancing drugs, increasing the quality, safety and access to patients and at a reduced cost.

Follow MilliporeSigma on Twitter @MilliporeSigma, on Facebook @MilliporeSigma and on LinkedIn.